Advancements in AI-based CT-FFR Analysis with DEEPVESSEL FFR: A Comprehensive Research Overview
Keya Medical’s AI CT-FFR Analysis: focus on its research and publications journey since DEEPVESSEL FFR FDA-clearance.
Keya Medical at 2024 ECR Annual Congress-Next Generation Radiology.
Take advantage of the opportunity to participate in a personalized one-on-one discussion with Keya Medical and explore a product demonstration.
DEEPVESSEL FFR Achieves Global Milestone with Four Certifications
On December 27, 2023, Keya Medical's CT FFR product DEEPVESSEL FFR (DVFFR) passed the certification of the Health Sciences Authority (HSA) of Singapore and was officially launched in Singapore! This is a breakthrough for Keya Medical’s artificial intelligence medical...
Keya Medical Presents FDA-cleared CT FFR product at SCCT Global 2024 | Budapest
Visit Keya Medical’s booth at SCCT Global 2024 in Budapest, January 16-19.
Scaling your Cardiovascular CT Service and Implementing CT-FFR
Discover the power of automated CT-FFR integration in enhancing your cardiovascular CT services.
Enhancing Cardiovascular Care: The Story of DEEPVESSEL FFR by Keya Medical
Keya Medical’s DEEPVESSEL FFR offers a non-invasive, accurate, and efficient solution for assessing coronary artery function. The product’s journey from inception to global clearances reflects a commitment to advancing medical technology and improving patient outcomes...
Keya Medical Covers Technology Advancements and AI Integration at SCCT 2023: A Look at Exceptional Collaborations.
In the dynamic landscape of medical innovation, SCCT 2023 served as an exceptional platform for exchanging cutting-edge insights and breakthroughs in cardiovascular technology.
Clinical Validation of DEEPVESSEL® FFR: AI CT-FFR Analysis by Keya Medical
The ADAPT Study: Assessment of the DiAgnostic Performance of DeepVessel FFR in SuspecTed Coronary Artery Disease SUMMARY DEEPVESSEL FFR is a medical device that is designed to extract three- dimensional coronary tree structures and generate computed tomography-derived...
TARGET Randomized On-Site CT FFR Trial Results
New data from the TARGET trial, the first randomized trial to assess on-site machine learning-based CT-FFR strategy in CAD management.
Keya Medical’s CT FFR analysis DEEPVESSEL® is now available in the USA.
Deep-learning-based, non-invasive, accurate, and accessible FFR CT analysis DEEPVESSEL FFR is now available in the USA.
The future of AI-driven, noninvasive CT FFR technology-DeepVessel FFR at 2022 cardiology events in China
Keya Medical US celebrates the achievements of the team in China and their commitment to the commercialization of DEEPVESSEL FFR.
DEEPVESSEL FFR, Keya Medical Deep-Learning Based, Non-Invasive Coronary Artery Functional Assessment Software Device, Receives FDA Clearance.
Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).
